Oxykodon/Naloxon Sandoz

Active Ingredient:: Naloxone Hydrochloride, Oxycodone Hydrochloride
Origin:: EU

Oxykodon/Naloxon Sandoz (Naloxone Hydrochloride, Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Naloxone Hydrochloride, the active ingredient in Oxykodon/Naloxon Sandoz, is an opioid antagonist presented as a combination formulation for oral use. It is used together with oxycodone hydrochloride to manage pain while reducing the risk of opioid‑induced respiratory depression in adult patients. GNH India supplies Oxykodon/Naloxon Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH India supplies Oxykodon/Naloxon Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Sandoz S.R.O.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxykodon/Naloxon Sandoz combines two agents that act on the opioid pathway to provide balanced pain control and safety.

Moderate to severe acute pain: improves analgesia while limiting opioid‑related respiratory depression.
Post‑operative pain management: provides effective pain relief after surgery with built‑in opioid antagonism.
Cancer‑related pain: offers strong analgesia for breakthrough pain with reduced risk of overdose.
Chronic non‑cancer pain: used in selected patients requiring high‑dose opioid therapy under close supervision.

How It Works

The product contains oxycodone, a μ‑opioid receptor agonist that produces analgesia by inhibiting pain signal transmission in the central nervous system. Naloxone is a competitive antagonist at the same μ‑receptor; when absorbed systemically it rapidly displaces oxycodone, limiting respiratory depression and other opioid‑related adverse effects while preserving analgesic benefit at the intended dose ratio.

Side Effects

Adverse reactions may occur with any opioid combination product. Monitoring is essential, especially during dose adjustments.

Common Side Effects

Nausea and vomiting: mild to moderate gastrointestinal upset.
Constipation: reduced bowel motility common with opioid use.
Dizziness or light‑headedness: transient vestibular effects.
Drowsiness or sedation: may affect alertness.
Dry mouth: reduced salivary flow.
Sweating: increased perspiration.

Serious or Rare Side Effects

Respiratory depression: reduced breathing effort, especially if naloxone effect wanes.
Severe hypotension: sudden drop in blood pressure.
Allergic reactions: rash, itching, swelling, or anaphylaxis.
Seizures: rare neurologic events.
Cardiac arrhythmias: abnormal heart rhythms.
Hepatic dysfunction: elevated liver enzymes or liver injury.

Precautions & Warnings

When prescribing Oxykodon/Naloxon Sandoz, clinicians should consider patient‑specific factors and follow safe‑use guidelines.

Assess pain severity and opioid tolerance: ensure appropriate indication before initiating therapy.
Monitor respiratory function: especially during initiation and dose changes.
Evaluate for history of substance abuse: adjust monitoring frequency accordingly.
Avoid concurrent central nervous system depressants: limit additive sedation risk.
Educate patients on signs of overdose and naloxone action.
Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Oxykodon/Naloxon Sandoz may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

Other opioids: may overwhelm naloxone antagonism, increasing overdose risk.
Benzodiazepines or barbiturates: additive respiratory depression.
MAO inhibitors: heightened serotonergic effects.

Moderate Interactions (Monitor Closely)

CYP3A4 inhibitors (e.g., ketoconazole): increase oxycodone plasma levels.
CYP3A4 inducers (e.g., rifampicin): reduce oxycodone effectiveness.
Anticholinergic agents: may worsen constipation.
Diuretics: potential for enhanced hypotensive effect.
Alcohol: increases sedation and respiratory risk.

Frequently Asked Questions

Oxykodon/Naloxon Sandoz is a fixed‑dose combination of oxycodone, a strong opioid analgesic, and naloxone, an opioid antagonist. It is prescribed to treat moderate to severe pain, such as post‑operative or cancer‑related pain, while reducing the risk of opioid‑induced respiratory depression.

Naloxone hydrochloride is a competitive antagonist at the μ‑opioid receptor. When absorbed systemically, it displaces oxycodole from the receptor, quickly reversing opioid‑related respiratory depression while allowing the prescribed analgesic effect of oxycodone to remain at the intended dose ratio.

The specific dose of Oxykodon/Naloxon Sandoz is determined by the prescribing clinician based on the patient’s pain severity, opioid tolerance, and overall clinical condition. Healthcare professionals adjust the dosage to achieve effective analgesia while monitoring safety.

Use of this combination during pregnancy or lactation should be approached with caution. Opioids can affect fetal development and may be excreted in breast milk. Clinicians must weigh potential benefits against risks and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike single‑agent opioids, this combination includes naloxone to mitigate opioid‑induced respiratory depression. This built‑in safety feature can reduce the need for separate rescue medications, offering a more balanced risk‑benefit profile for patients requiring strong analgesia.

Store the product at temperatures below 25°C in its original packaging. Protect it from moisture, direct sunlight and excessive heat to maintain potency and stability.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.